<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cardiovascular Pharmacology</title>
    <link rel="stylesheet" href="../../../css/main.css">
    <link rel="stylesheet" href="../notes_pages.css">
    <link rel="stylesheet" href="cv_styles.css">
    <style type="text/css">
        
    </style>
</head>

<body>
    <h1>Cardiovascular Pharmacology</h1>
    <hr>
    <br>
    <div class="ToC">
        <span id="ToC">Table of Contents</span>
        <ol class="ToC">
            <li>Hypertension therapies
            <ol>
                <li><a href="#ace_inh">Angiotensin&#x2011;Converting Enzyme (ACE) Inhibitors</a></li>
                <li><a href="#arb">Angiotensin &#x2161; Receptor Blockers (ARBs)</a></li>
            </ol>
            </li>
        </ol>
    </div>
    <div class="drugs">
        <h2>Hypertension therapies</h2>
        <h3 id="ace_inh" style="margin-top: 0.5em;">Angiotensin&#x2011;converting Enzyme Inhibitors</h3>
        captopril, enlapril, lisinopril, ramipril
        <table class="pharm">
            <tr>
                <td>MECHANISM OF ACTION</td>
                <td>&#x22A3; ACE &rarr; &darr; AT&#x2161; &rarr; &darr; GFR by preventing constriction of efferent arterioles<br>
                    &#8627;&nbsp;&uarr; renin due to loss of negative feedback<br>
                    &#8627;&nbsp;prevents inactivation of bardykinin, a potent vasodialtor
                </td>
            </tr>
            <tr>
                <td>CLINICAL USE</td>
                <td>HTN, HF (&darr; mortality)<br>
                    &#8627;&nbsp;prevent unfavorable heart remodeling from chronic HTN<br>
                    Proteinuria, diabetic nephropathy
                </td>
            </tr>
            <tr>
                <td>ADVERSE EFFECTS</td>
                <td>Heavier or longer menses, dysmenorrhea. Risk of PID with insertion</td>
            </tr>
            <tr>
                <td>CONTRAINDICATIONS</td>
                <td>CATCHH:
                    <ul>
                        <li>Cough,</li>
                        <li>Angioedema,</li>
                        <li>Teratogen,</li>
                        <li>&uarr; creatinine,</li>
                        <li>Hyperkalemia</li>
                        <li>Hypotension</li>
                    </ul>
                </td>
            </tr>
        </table>
        <h3 id="arb"><a href="renal_phys.html#AT2R">Angiotensin &#x2161; Receptor</a> Blockers (ARBs)</h3>
        losartan, candesartan, valsartan
        <table class="pharm">
            <tr>
                <td>MECHANISM OF ACTION</td>
                <td>Selectively block binding of angiotensin &#x2161; to AT<sub>1</sub> receptor<br>
                    &#8627;&nbsp;similar effects to ACEi, but ARBs don't &uarr; bardykinin
                </td>
            </tr>
            <tr>
                <td>CLINICAL USE</td>
                <td>HTN, HF, proteinuria, chronic kidney disease with intolerance to ACEi
                </td>
            </tr>
            <tr>
                <td>ADVERSE EFFECTS</td>
                <td>Heavier or longer menses, dysmenorrhea. Risk of PID with insertion</td>
            </tr>
            <tr>
                <td>CONTRAINDICATIONS</td>
                <td>Hyperkalemia, &darr; GFR, hypotension, teratogen
                </td>
            </tr>
        </table>
    </div>

</body>
</html>